A New Kind of Clinical Research Requires a New Kind of CRO:
Powered by Data and Built to Perform.
A New Kind of CRO That Is Ready for…
Defining crucial solutions for digital therapeutics
Running Digital Therapeutics trials challenge traditional processes and demands a CRO with experience and adaptability to navigate regulations, design studies and quality data to accelerate development.
Is your CRO ready to answer your questions on digital therapeutics?
The new realities of precision medicine
Technology has radically altered the path of treatment. Cheaper genetic sequencing and the advent of new biomarkers has opened the door to personalized, targeted medicine, but also to a new reality of difficult recruitment and extremely complex protocols.
Is your CRO ready for the new realities of precision medicine?
The unique challenges of rare disease trials
Treatments for rare disease make up more than half of annual drug approvals. These clinical trials bring new challenges with patient populations that are small and globally dispersed. Successfully completing these trials requires a partner designed to navigate these complexities.
Is your CRO ready for the unique challenges of rare disease trials?
What Defines A New Kind of CRO?
Programs, Not Trials
You think in terms of programs and pipelines, not individual trials. We do, too. We seek to support your entire development program, not just the trial in front of us.
We don’t allow tunnel vision to set in. Biorasi is constantly looking for ways to help you optimize and improve your entire therapeutic pipeline. From finding new regulatory pathways and venues, to identifying follow-on indications.
Patients, Not Sites
Your challenge is recruiting the right patients, not finding the right sites. Our challenge is to help you find those patients wherever they are.
Thinking in terms of patients allows us to break away from the traditional reliance on sites and go directly to where your patients are. The result is faster recruitment of higher quality patients, especially in complex and difficult to recruit trials.
Data Science, Not Data Management
Your trials generate a lot of data – over 3 million individual points. But is that data being harnessed to help your trial and your program?
We leverage advanced analytics and techniques inspired by big data processing to put your clinical data to work. Instead of just collecting, we process from the beginning, giving you deep insights and a strategic advantage from the start.
Transparency, Not Reporting
Your trials run 24/7, with new activity daily. So why do you only get reports once a week, if that? Knowing that your trial is on track requires transparency unlike anything the industry has seen.
We believe that you should own your data, and should be able to access it anytime and anywhere, in real time. Our TALOS™ Control Center gives you minute by minute updates, so you know what’s happening right now, not just last week.
Structured Methodology, Not Ad-Hoc Project Management
Clinical research is becoming more complex, while the level of clinical project management stays the same. This divergence is not sustainable.
We began with a structured methodology to clinical project management and certified project management professionals. It’s why we are able to deliver your trials on time and on budget, and why we can say there are many rescues that are never rescued.
Our Core Values
Relentlessly Pioneering
____
You pioneer the science, Biorasi pioneers a better approach to clinical research. We push the boundaries of complex trials, and find ways to improve your whole program.
Insanely Efficient
____
We were built to be smarter, faster, better. More integrated in our teams and our technology. Making better use of your data. And delivering better results.
Fearlessly Accountable
____
We give our sponsors unparalleled transparency into their trials. Best in class tools like the TALOS™ Control Center give you full ownership and hold us accountable to deliver.
Partner Obsessed
____
Your success is our success, and your priorities are our priorities. We don’t believe in the terms “client” and “vendor” – we believe in building true lasting partnerships.
Talk with us
Latest Publications
NORD Breakthrough Summit: 3 Key Takeaways
A team from Biorasi joined more than 900 leaders from the FDA, NIH and the pharma and bio-pharma industries for the National Organization for Rare Disorders (NORD) & Orphan Products Breakthrough Summit....
Strategies for Successful Digital Therapeutics Clinical...
As digital therapeutics are integrated into every aspect of the healthcare landscape, patients, payers, and providers are seeing an increasingly complex set of software-driven therapy options reaching the market. This rapidly expanding...
Acute Kidney Injury (AKI): Management and...
In my previous article, I explained the types, causes and symptoms of Acute Kidney Injury (AKI). Here, I’ll share how physicians treat and manage AKI, as well as what to expect. CRRT...
Acute Kidney Injury (AKI): Why aggressive...
What is AKI? AKI is a sudden, reversible decline in the kidney’s glomerular filtration rate (GFR); in other words, its ability to filter metabolic waste. This kidney damage causes an elevation of...
Rare Disease: 5 Steps to Successful...
There may be as many as 7,000 rare diseases. The European Union defines a disease as rare when it affects less than one in 2,000 people. According to the Orphan Drug Act,...
Precision Medicine: What can we learn...
To execute precision medicine clinical trials, sponsors have adopted a range of new approaches, especially in early-stage studies. Many of these models allow sponsors to recruit more patients and bring drugs to...
How to Use Proven Methodologies to...
As clinical trials become more complex and costly, the need for skilled project managers to oversee them is more important than ever. Project management methodologies drive success for enterprise organizations in all...
Orphan Drugs and Rare Diseases Global...
Biorasi will be at the 2019 Orphan Drugs and Rare Diseases 2019 Americas – West Coast from July 23rd - 24th 2019 in San Francisco, CA, USA. We would like to extend...
FSGS: A rare kidney disease without...
Researchers are studying a few new and existing drugs to treat FSGS. FSGS needs a novel medication that regulates both high body fats and inflammasome inhibition via upstream innate immune system to...
Is targeted gene therapy in Neurology’s...
To unlock more targeted, effective treatments, genetics researchers are exploring mutations responsible for some of the most common motor neuron diseases. These discoveries may lead to gene therapy treatment routes that do...
Biorasi Center of Excellence Spotlight: Oncology
Biorasi’s Oncology Center of Excellence remains at the forefront of this exciting field. Our team of clinicians, program managers and other experts stay up to date on the latest developments, from Tumor...
How Dermatology Research Gaps Represent Untapped...
Gaps in dermatological research present potentially lucrative market opportunities for pharmaceutical companies. Patients that suffer from skin conditions and diseases also benefit. Effective treatments relieve irritating, chronic, and often painful symptoms, which...
How the Right Oversight Assures Clinical...
A clinical trial's operational efficiency depends on a solid oversight and response mechanism. Without vigilant monitoring, patient safety, data integrity, and the overall health of your trial come into jeopardy.
How to Launch a Successful, Cost-Effective...
How to run a more efficient pediatric clinical trial: Although pediatric trials overall cost roughly the same as adult clinical trials according to one analysis, they generally produce a more modest return...
Rare Disease Spotlight: C3 Glomerulopathy
C3 glomerulopathy (C3G), a rare kidney disease, affects only two or three people out of every one million. That’s only a couple people out of the entire population of San Jose, California...
Prepare for Success: How Advance Planning...
Why Do So Many Clinical Trials Fall Behind? Clinical trials are not immune to missed deadlines and cost overruns. However, with proper advance planning, you can up the odds of success and...
Modern Challenges in Movement Disorders Clinical...
Movement disorders such as Parkinson’s disease, ataxias, tremor, dystonia, tics, Tourette’s, and dozens of rare diseases, affect nearly 40 million Americans. They’re usually chronic, often progressive, […]
Determining the “ROI” of Clinical Trial...
Have you ever put off talking to your significant other about expensive-but-necessary home repairs, for fear they’ll hit the (leaking) roof? Most of us have, and […]
The Power of Patient Registries: How...
Each year, doctors diagnose about 1,000 Americans with cystic fibrosis, a rare hereditary disease that affects about 30,000 people in the United States. Thanks to advances […]
Is Gut Microbiome Behind Our Next...
“Microbiome” has become a consumer product buzzword, found in advertisements for soap and dozens of foods that contain “friendly bacteria.” Meanwhile, the scientific community is discovering […]
Patient Recruitment Solution: How to Ease...
The numbers vary but multiple surveys confirm what we all know: patient recruitment is one of the most challenging and important aspects of running a clinical […]
Cellular Therapy in Neurological Diseases: The...
Neurological disorders and diseases affect all ages and ethnicities, and most result in long-term disability and irreversible conditions. A paper published in the Annals of Neurology reports the […]
Advances in Non-Opioid Options for Post-Operative...
In a statement last August, departing FDA Commissioner Scott Gottlieb outlined several steps the agency had planned to further address the opioid crisis. Part of that […]
Introducing Biorasi’s Center of Excellence: Neurology...
Advances in stroke management, the first cannabinoid-derived drug approved, new therapeutics for progressive multiple sclerosis, early signs of successful treatment of diabetes and myocardial infarct via […]
When Virtual Trials Are Not the...
Next to cost, patient recruitment, enrollment, and retention are top concerns for sponsors, sites, and others involved in clinical trials. Will virtual clinical trials ease these […]
Dermatology Detectives: How the Right Principal...
The principal investigator (PI) plays an important role in a clinical trial, regardless of therapeutic area. When conducting complex dermatology clinical trials with difficult to treat, […]
How to Minimize Subjectivity in Dermatology...
The success of any clinical trial depends on unbiased data. However, the subjective nature of many dermatology assessments makes unbiased data harder to come by. Inconsistent […]
Is Your Clinical Trial in Need...
Recognizing early warning signs that your trial is in trouble, and taking quick decisive action, can often get studies back on track. Improving operations can solve most failure risk factors, thus increasing...
Cosmeceuticals: How to Navigate the Legal...
The cosmeceuticals market continues its steady climb upward—a rise in disposable income plays a role, as well as the introduction of new ingredients that promise anti-aging, […]
What is the Skin Microbiome?
A current Dove soap ad asks, “Is your body wash microbiome gentle?” Do you need microbiome gentle soap? And what is your skin microbiome anyway? We’ll […]
Challenges in Dermatology Device Clinical Trials...
Rising concerns about aesthetics has led to increased demand for hair- and skincare procedures. In addition, rates of skin disorders such as psoriasis, acne, eczema, and […]
The Current Standing of Research on...
Wound healing is a complicated and dynamic process that includes multiple overlapping phases. Adequate wound healing is crucial to avoid risk of infections, prolonged hospitalization, […]
Post-Brexit Implications for the Pharmaceuticals Industry
On June 23, 2016, United Kingdom (UK) voters decided to leave the European Union (EU) in the closely fought Brexit (British+Exit) referendum. Although a withdrawal deal, […]
Press Release: Leading Global CRO Hires...
Celebrated Industry Veteran to Lead Scientific, Medical, and Regulatory Affairs at Biorasi Miami, FL, Jan 29, 2019 (GLOBE NEWSWIRE via COMTEX) — Miami, FL, Jan. 29, […]
Rescue Is Not A Dirty Word:...
3 Measures to Overcome Operational Failures Every year, tens of thousands of clinical trials are initiated. Every year, thousands of those trials falter, and, if corrective […]
What Are The Advantages of Virtual...
In this blog post, we will try to understand Virtual Clinical Trial. As technology continues to become better and more integrated into the clinical development industry […]
SCOPE 2019
Biorasi will be attending and exhibiting at the SCOPE 2019 Annual Meeting from February 18-21 in Orlando, FL. We would like to extend a cordial invitation […]
AAD 2019
Biorasi will be attending and exhibiting at the AAD 2019 Annual Meeting from March 1-5 in Washington, DC. We would like to extend a cordial invitation […]
Introducing Biorasi’s Center of Excellence: Dermatology
Biorasi has a solid track record of experience in dermatology, and our goal for this year is to share all corners of our knowledge on the […]
AAN 2019
Biorasi will be attending the AAN 2019 conference from May 4-10 in Philadelphia, PA. We would like to extend a cordial invitation to all of our […]
BIO International 2019
Biorasi will be attending and exhibiting at the BIO 2019 conference from June 3-6 in Philadelphia, PA. We would like to extend a cordial invitation to […]
DIA Global 2019
Biorasi will be attending and exhibiting at the DIA 2019 Global Annual Meeting from June 23-27 at the San Diego Convention Center. We would like to […]
Immuno-Oncology Summit 2019
Biorasi will be attending and exhibiting at the Immuno-Oncology 2019 summit from August 5-9 in Boston, MA. We would like to extend a cordial invitation to […]
World ADC 2019
Biorasi will be attending World ADC 2019 from October 10-11 in San Diego, CA. We would like to extend a cordial invitation to all of our […]
CNS Summit 2019
Biorasi will be attending CNS Summit 2019 from October 31 – November 3 in Boca Raton, FL. We would like to extend a cordial invitation to […]
ASN Kidney Week 2019
Biorasi will be attending and exhibiting at the Kidney Week 2019 conference from November 5-10 in Washington, D.C. We would like to extend a cordial invitation […]
ASH 2019
Biorasi will be attending ASH 2019 from December 7-10 in Orlando, FL. We would like to extend a cordial invitation to all of our partners, sponsors, […]
Commonalities of Rare Diseases
Collectively, rare diseases affect a huge number of people: about 25 million in the US and 400 million globally. To qualify as a rare disease per […]
New FDA Guidance for NASH Drug...
Just in time for our final follow-up to the two previous articles on non-alcoholic steatohepatitis (NASH), the FDA released a new draft guidance for drugs being […]
Press Release: Biorasi Partners with RLH...
Florida-Based CRO seeks to expand offerings, global footprint, and headcount after successful investment transaction. Biorasi, a leading full-service global contract research organization (CRO), is excited […]
The Future of Diabetes Treatment
Type 1 diabetes affects millions of people in the US alone. What’s worse is that the majority of patients do not achieve good control of their […]
A Deep Dive into NASH Physiology...
In the clinical trial world, we spend a lot of time focusing on phase I-IV trials, and it’s easy to forget about the very important preclinical, […]
How Virtual Trials Support Patient-Centricity
Revolutionizing Clinical Research: How Virtual Trials Support Patient-Centricity In this digital age, virtual trials may very well become the norm at some point in the future, […]
How Managers Can Establish Good Working...
Authors: Geetesh Shrivastava, Associate Director of Clinical Monitoring; Jennifer Dennis-Wall, PhD, Lead Scientific Writer Back in August, we published a blog addressing themes that are important […]
Considerations for Working with Research-Naive vs....
When recruiting patients with hard-to-enroll indications, such as rare diseases, it is sometimes necessary to dip into creative resources for finding sites. Sometimes this means looking […]
Why Aren’t There Any FDA-Approved Drugs...
The liver does many important things in the body, such as filtering of the blood and metabolizing all compounds, including food and drugs, that enter the […]
10 Lessons On Success in Asia-PAC...
Earlier this year, a few of us attended DIA 2018 to represent Biorasi. While there, we were fortunate enough to be able to give a talk […]
You’re Holding Your Eye Drops Wrong...
Last week, one of our resident experts in ophthalmology, Ignacio Handal, gave a training for some of our current studies with a focus on which pitfalls […]
A More Complete Scope for Advances...
When people think about women’s health, especially during the month of October, they may think only of breast cancer or reproductive disorders. The truth, though, is […]
The Politics of Investigator-Initiated Trials
Many clinical trials are initiated by a pharmaceutical company in order to generate data to submit to the FDA for drug approval. Investigator-initiated trials (IITs), on […]
Six Things We Can Do Now...
“What we need to do is to keep working on getting biomarkers more defined to be able to differentiate between the different etiologies. This is going […]
The Tumultuous History of Women’s Involvement...
Inclusion of women in clinical research has a surprisingly colorful history. As you can probably imagine, inequality is present throughout, but for reasons that may not […]
Managing Alzheimer’s Trials in a Diverse...
Patients with Alzheimer’s are not treated the same everywhere. On a global level, this is immediately evident between countries through differences in diagnostic criteria. Even on […]
Five New Tech Options to Use...
Have you heard of virtual clinical trials? They are trials in which patients can do most of their study activities from home instead of traveling to […]
How are Adaptive Trial Designs Improving...
The ability to adapt is a valued attribute in today’s constantly changing world, and clinical trial designs are no exception. Adaptive trial designs can save sponsors […]
Reservations Held by Referring Physicians in...
Some physicians are reluctant to participate in clinical trials as a referring physician. This is a huge issue because a large portion of participants can come […]
Advanced Analytics for the Monitoring of...
Advanced Analytics for the Monitoring of Clinical Trials What if there was a way to harness all this data we’re collecting and turn it into a […]
Five Lesser-known Facts about Sun Exposure
Labor Day weekend is upon us! This means that many of us will be outdoors, if we’re lucky. Methods for preventing sun damage have not changed […]
Don’t Let Summer Obstacles Catch You...
There are physiological and logistical challenges to running studies in the summer. We present some solutions.
Biorasi Joins Nova Southeastern University to...
Leading Florida-based Contract Research Organization Partners With University to Train Tomorrow’s Medical Research Professionals Miami, FL, Aug. 09, 2018 (GLOBE NEWSWIRE) — Biorasi, a leading full-service […]
Eight Sponsor Essentials for a Successful...
It’s pretty common for a pharmaceutical company to have a list of demands ready when choosing a CRO partner for a clinical trial. Here at Biorasi, we have some demands of our...
Using Precision Medicine in Cancer Trials
Why is it that when we take 50 people of similar height and weight and measure their fasting blood glucose, we get 50 different results? Shouldn’t […]
The Future is Here for Clinical...
Mobile phone apps and wearable devices have a lot of potential to improve clinical studies. However, the rules governing them are complex, varied, and not fully […]
Site Selection Process—How the balance of...
Site selection is one of the most important steps in the clinical trial process; nevertheless, it can be the most daunting. With over 272,000 registered clinical […]
An Animal Study That You Won’t...
A recent study is making history in the field of Alzheimer’s research. For a long time, scientists have been trying to understand how neurodegenerative diseases, such […]
Teamwork: An Evidence-Based Approach for Trial...
Every clinical trial comes with its own unique challenges. Sometimes the biggest challenge faced by a trial is simply not enrolling enough participants. Well-documented reasons for […]
Biorasi Spotlight: Iulia Tath – Intern
For this week’s Biorasi Spotlight, meet Iulia Tath, Intern, at Biorasi, LLC. How did you become interested in clinical research? As an undergraduate student majoring in […]
Biorasi Recognized for Best in Class...
Biorasi is proud to announce that leading industry publication Global Health & Pharma, also known as GHP News, has recognized the company twice in their 2017 […]
Bolstering Enrollment in Parkinson’s Trials: Patient...
Novel treatments, accurate biomarkers and efficient diagnostic tests are direly needed in the fight against Parkinson’s Disease (PD), the second leading neurodegenerative disease in the world. […]
Special Considerations for Clinical Trials in...
Clinical trials in neurological diseases often mirror the complexity of the disease itself. Hence, a team tackling this type of clinical trial should make a number […]
Non-Traditional Trial Recruitment Strategies for Non-Traditional...
Innovative and out of the box methods are often required for the recruitment of challenging populations in clinical trials that would otherwise fail miserably when using […]
Tweaking Study Designs to Increase Enrollment...
Many of us typically think of Alzheimer’s Disease (AD) when we hear the word “dementia”. This is a fair assumption since AD is indeed the most […]
An Intern’s Glimpse into the World...
As a Master of Health Administration (MHA) candidate at the University of Miami and a Program Development intern at Biorasi for the last four months, I […]
What to Look for When Selecting...
Risk-based monitoring (RBM) is heralded as the new solution to all troubles in clinical research – the exorbitant complexity, the ridiculous costs, the nerve-wracking SAEs. Sponsors […]
Not Enrolling Enough? How to Rescue...
A common issue regarding “faltering” studies – studies that are not satisfying their time, cost, and quality parameters – is poor recruitment. Recruitment issues can delay […]
Avoiding the Blame-Game in Rescue: Don’t...
Introduction Clinical trial rescues can often be a delicate topic for both sponsor and contract research organization. When a study goes off track, it’s natural to […]
Dermatology Expertise Helps Biorasi Recruit In...
Dermatology Expertise Helps Biorasi Recruit In Challenging Conditions Intelligent Processes Overcome Enrollment Barriers The Challenge: Patient compliance was a serious concern, particularly regarding the reduction of […]
Stem Cells?! What are they? How...
Introduction Stem Cell Therapy is one of the most important biomedical discoveries in recent history, with far-reaching potential effects on a wide range on individuals afflicted […]
Holiday Hurdles in Clinical Research
With the holiday season upon us, the focus shifts from daily work tasks to planning for vacations and festivities. The holidays can be especially challenging in […]
Strict Processes Rescue Complex MS Trial
Strict Processes Rescue Complex MS Trial Biorasi’s Project Management-first Approach Allows Rapid Feasibility and Site Startup to Meet Critical Deadlines The Challenge: A specialty pharmaceutical company […]
Stem Cells: Myths and Misconceptions in...
Stem Cell therapy constitutes one of the most hailed advents in medicine for its potential in treating many of the chronic and difficult diseases like Traumatic […]
Quintessential Guide to Planning a Clinical...
The Quintessential Guide to Planning a Clinical Trial Clinical trials are complex undertakings, with complex planning required. Success or failure is often determined long before the […]
Pioneers Tackling Interchangeability in Biosimilars
With a global market of USD 3.3 billion during 2016 and a forecast surpassing USD 10.5 billion by 2023, Biosimilars have received more than their fair […]
The IgAN Enigma
Immunoglobulin A (IgA) is an antibody manufactured by the body’s immune system to protect against invaders. Immunoglobulin A nephropathy (IgAN) is a common kidney disease where […]
Breast Cancer Month: Better Trial Enrollment...
Despite an extremely encouraging 38% decrease in mortality since 1989, Breast Cancer remains the most common type of cancer in the US. Indeed, it is estimated […]
Upcoming Advancements in the Treatment of...
Approximately 60,000 Americans are diagnosed with Parkinson’s disease each year, and more than 10 million people worldwide are living with Parkinson’s disease (PD). With no predictive […]
Reprogramming the Mind: Virtual Reality Exposure...
According to the CDC, post-traumatic stress disorder (PTSD) is one of the most common mental disorders present in the general population. In the United States an […]
Skin So Simple: Myth Busted
Clinical research in dermatology has a reputation for being simple and easy to conduct compared to other therapeutic areas. Developing therapies for the largest organ in […]
A Modern Approach to Patient education...
A Modern Approach to Patient Education Increases Enrollment Interactive Solution Increases Enrollment And Compliance With Injectables Download Case Study The Challenge:Running a trial for dermatology injectables […]
Traial Planning Save ALBP Trial some...
Biorasi Rescue Effort Doubles CNS Trial Enrollment Rate Leveraging experience to predict problems before they affect clinical trial deliverables Download Case Study The Challenge:Not every study […]
Biorasi’s TALOS™ Platform and Unique Sites...
Biorasi’s TALOS™ Platform and Unique Site Win Unusual ANDA Trial Flexibility and Strong Process-driven Planning Overcomes Regulatory Speedbumps Download Case Study The Background:ANDA approval for therapies […]
Putting CDISC Standards to Work
The CDISC set of standards revolutionized data management in clinical trials by introducing a standardized model for data interoperability. The standard has been shown to decrease study data resource requirements by 60%...
Operating a Pharmacovigilance Group in a...
Operating a Pharmacovigilance Group in a Multicultural Global Environment The way an individual interprets language is influenced by many factors, including culture, background, education, training, and […]
Optimizing Ophthalmic CE ANDA Trials
Optimizing Ophthalmic CE ANDA Trials Clinical Endpoint ANDA Program Optimization White Paper Series Download White Paper
Navigating through the Clinical Trial Authorization...
Navigating through the Clinical Trial Authorization Process in Russia Clinical Endpoint ANDA Program Optimization White Paper Series Download White Paper
Patient Numbers Required In Clinical Endpoint...
Patient Numbers Required In Clinical Endpoint ANDA Trials Clinical Endpoint ANDA Program Optimization White Paper Series Download White Paper
Optimizing the Amount of Investigational Materials...
Optimizing the Amount of Investigational Materials in ANDA Studies – Part Two For Dermal Semisolid Clinical Studies White Paper Series Download White Paper
Optimizing the Amount of Investigational Materials...
Optimizing the Amount of Investigational Materials in ANDA Studies – Part One Clinical Endpoint ANDA Program Optimization White Paper Series Download White Paper
Five Signs Your Clinical Trial Needs...
By some estimates, more than 90% of drug candidates never make it into consumer hands. That number shouldn’t come as a surprise to anyone who has […]
Emerging Challenges in Global Clinical Studies
Clinical research is going global. This growth translates to sponsors no longer running separate studies in each and every country they are seeking marketing approval; instead […]
Advances in Early Alzheimer’s Detection
The prevalence of Alzheimer’s disease (AD) is rapidly increasing as individual life spans across the world increase. It is currently the most common form of dementia, […]
Can Big Data Rescue Clinical Trials?
If you had to pick one buzzword that perfectly encapsulated the current latest and greatest in innovation, you could do a lot worse than “big data”. […]
Clinical Endpoint ANDA Program Optimization Introduction
Clinical Endpoint ANDA Program Optimization This introduction marks the launch of a series of White Papers dealing with the optimization of Clinical Endpoint ANDA Programs for […]
Trial Rescue Effort Doubles CNS Trial...
BIORASI RESCUE EFFORT DOUBLES CNS TRIAL ENROLLMENT RATE Patient Enrollment Needs To Be Strategic, Not Just Tactical Download Case Study Almost every company that has ever […]
3 Trends in Biosimilars: A 6-Year...
Over the next five years, the purchase and production of biosimilar drugs can expect to see double-digit growth. As biosimilar drugs become more widely produced, prescribed, used, […]
The Most Common Reasons for Trial...
The study is behind schedule. Enrollment is lagging. The protocol is too complicated. Approximately 80 percent of all clinical studies need intervention or optimization to be successful, […]
Implement CDISC Standards for Faster Reporting...
The Clinical Data Interchange Standards Consortium (CDISC) created standards designed to streamline clinical research data and essentially enable reviewers to more fully assess the efficacy and […]
The Promise of Biosimilar Drugs
In 2006, the European Medicines Agency granted its first approval of a biosimilar drug, the human growth hormone, Omnitrope™ (Sandoz), and opened the doors of opportunity for this […]
Creating High Performance Pharmacovigilance Teams in...
Individuals often interpret the same information and terms in dramatically different ways. Multiple factors drive these variances, including culture, background, education, training, and personal biases. Unfortunately, […]
Biorasi Joins GPhA Biosimilars Council to...
There is great strength in numbers, and joining forces with some of the world’s most influential companies in the biosimilar industry will position Biorasi to have […]
Clinical Research Optimized ™ Powered by...
Biorasi delivers Clinical Research Optimized ™ for Biosimilar clinical trials, proving success in some of the most complex trials in the industry. Multi-dimensional trial challenges require […]
June is Men’s Health Awareness Month
Biorasi  conducts life-impacting drug studies for Men’s Health; now, if they only showed up to the Doctor. Biorasi is taking the opportunity in June, Men’s Health Awareness Month, to encourage men and […]
It’s your life; live it well....
It’s your life; live it well. Healthy Options are Key It can be hard to maintain a healthy lifestyle when working traditional 9-5 business hours. It […]
Mental Health Awareness, Part 2: Spotlight...
In September 2014, TIME called Iodine “The Yelp of Medicine,” founded by former Wired editor, Thomas Goetz and Google engineer, Matt Mohebbi, the startup offers a […]
Mental Health Awareness, Part 1: #B4Stage4
1 in 5 American adults will have a diagnosable mental health condition in any given year. 50% of Americans will meet the criteria for a diagnosable […]
Parkinson’s Disease, Part 3: The Importance...
Parkinson’s is a disease uniquely and inextricably tied to its community. Patients share symptoms, treatments, difficulties and experiences. Most importantly, they also share in the mystery […]
Job vs. Career? The Biorasi Difference
A few years ago the news and shelves were filled with articles about Millennials entering the work force. The general consensus seemed to be this new […]
Parkinson’s Disease, Part 2: Real-time health-tech...
As wearables gain popularity and health related applications rank higher on consumer needs; the health-tech industry is rapidly evolving. 2012 marked the new era of “health-tech” […]
Parkinson’s Disease, Part 1: The Importance...
Imagine: Losing total control of physical and mental motor skills Taking simple things for granted such as holding a pen, a hair brush or tying a […]
A Perfect Match
Today we can do more on our smartphones than desktop computers could a mere ten years ago. Smartwatches have officially left the idea boards and have […]
Aiming Higher in Dermatology Clinical Trials
Let’s start with the basics. Dermatology is the branch of medicine dealing with hair, skin, nails and all its diseases. At a very simplified level, Dermatology […]
